Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.
Cilengitide, a cyclic RGD pentapeptide, is currently in clinical phase III for treatment of glioblastomas and in phase II for several other tumors. This drug is the first anti-angiogenic small molecule targeting the integrins αvβ3, αvβ5 and αvβ1. It was developed by us in the early 90s by a novel procedure, the spatial screening. This strategy resulted in c(RGDfV), the first superactive αvβ3 inhibitor (100 to 1000 times increased activity over the linear reference peptides), which in addition exhibited high selectivity against the platelet receptor αIIbβ3. This cyclic peptide was later modified by N-methylation of one peptide bond to yield an even greater antagonistic activity in c(RGDf(NMe)V). This peptide was then dubbed Cilengitide and is currently developed as drug by the company Merck-Serono (Germany). This article describes the chemical development of Cilengitide, the biochemical background of its activity and a short review about the present clinical trials. The positive anti-angiogenic effects in cancer treatment can be further increased by combination with "classical" anti-cancer therapies. Several clinical trials in this direction are under investigation.
Institute for Advance Study, Department Chemie, Technische Universität München, Garching, Germany.
Carlos
C
Mas-Moruno
Florian
F
Rechenmacher
Horst
H
Kessler
D020533:Angiogenesis Inhibitors / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D015195:Drug Design; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors / Q000378:metabolism; D008958:Models, Molecular; D009369:Neoplasms / Q000188:drug therapy*; D010456:Peptides, Cyclic / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D016023:Integrins; D010456:Peptides, Cyclic; C507169:cyclic arginine-glycine-aspartic acid peptide
Methods Enzymol. 2007;426:463-503
17697896
Nat Med. 2009 Jul;15(7):726; author reply 727
19584855
Brain Pathol. 2008 Jul;18(3):378-86
18394009
J Cell Biol. 1989 Jun;108(6):2519-27
2738096
J Med Chem. 2004 Aug 12;47(17):4166-77
15293989
J Cell Biol. 2001 Oct 29;155(3):459-70
11684710
Br J Cancer. 2002 Mar 4;86(5):788-95
11875744
J Clin Invest. 1991 Jan;87(1):1-5
1985087
EMBO J. 1986 Nov;5(11):2805-8
2431898
J Biol Chem. 2000 Jul 21;275(29):21785-8
10801897
J Biol Chem. 1994 Aug 12;269(32):20233-8
8051114
Int J Cancer. 2011 May 15;128(10):2453-62
20648558
J Clin Oncol. 2010 Jun 1;28(16):2712-8
20439646
J Clin Oncol. 2008 Dec 1;26(34):5610-7
18981465
Cell. 1994 Dec 30;79(7):1157-64
7528107
Clin Genitourin Cancer. 2006 Mar;4(4):299-302
16729916
Mini Rev Med Chem. 2009 Oct;9(12):1439-46
19929817
Clin Cancer Res. 2005 Sep 1;11(17):6270-9
16144931
Proc Natl Acad Sci U S A. 1984 Oct;81(19):5985-8
6237366
Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii60-7
14532152
Angew Chem Int Ed Engl. 2008;47(14):2595-9
18297660
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1853-8
11172040
Mol Biol Cell. 1995 Jun;6(6):725-40
7579691
Eur J Biochem. 1992 Dec 15;210(3):911-21
1483474
Nat Rev Cancer. 2002 Feb;2(2):83-90
12635171
Am J Pathol. 2000 Apr;156(4):1345-62
10751360
Nat Med. 2002 Jan;8(1):27-34
11786903
Br J Cancer. 2004 Feb 9;90(3):561-5
14760364
BMC Cancer. 2006 Dec 11;6:285
17156477
Int J Cancer. 2000 Sep 1;87(5):716-23
10925366
Cancer Res. 2009 Apr 15;69(8):3308-16
19351861
Angew Chem Int Ed Engl. 2007;46(19):3571-4
17394271
Cell. 1986 Feb 28;44(4):517-8
2418980
N Engl J Med. 2005 Mar 10;352(10):997-1003
15758010
J Clin Oncol. 2008 Feb 20;26(6):919-24
18281665
J Cell Sci. 1990 Dec;97 ( Pt 4):585-92
2077034
Cell. 1998 Nov 13;95(4):507-19
9827803
Ann Oncol. 2007 Aug;18(8):1400-7
17693653
Expert Opin Drug Discov. 2010 Jul;5(7):655-71
22823205
Nat Rev Cancer. 2002 Jan;2(1):38-47
11902584
Nat Rev Mol Cell Biol. 2010 Apr;11(4):288-300
20308986
Nat Med. 2002 Mar;8(3):193-4
11875466
Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1536-43
16863930
Clin Cancer Res. 2006 Jul 1;12(13):3942-9
16818691
Curr Opin Investig Drugs. 2003 Jun;4(6):741-5
12901235
Curr Biol. 1999 Sep 23;9(18):1043-6
10508619
Biopolymers. 1976 Aug;15(8):1615-22
963253
J Cell Sci. 1997 Oct;110 ( Pt 19):2473-82
9410885
Development. 1993 Dec;119(4):1093-105
7508365
Acc Chem Res. 2009 Jul 21;42(7):969-80
19489579
Cell. 1981 Oct;26(2 Pt 2):259-67
6174240
Life Sci. 1982 Jul 19;31(3):189-99
6126794
Mol Biol Cell. 1993 Sep;4(9):953-61
8257797
J Biol Chem. 1987 Dec 25;262(36):17294-8
3693352
Nat Med. 2002 Sep;8(9):918-21
12205444
J Cell Sci. 2006 Oct 1;119(Pt 19):3901-3
16988024
Nat Rev Cancer. 2008 Aug;8(8):604-17
18497750
Thromb Haemost. 1999 Aug;82(2):481-5
10605739
PLoS Med. 2005 Mar;2(3):e70
15783258
J Am Chem Soc. 2010 Jun 16;132(23):8115-28
20496895
Nat Med. 1995 Feb;1(2):149-53
7585012
Nat Rev Cancer. 2002 Feb;2(2):91-100
12635172
Nat Med. 1995 Jan;1(1):27-31
7584949
Angew Chem Int Ed Engl. 2000 Aug 4;39(15):2761-2764
10934419
Nat Cell Biol. 2004 May;6(5):388-9
15122265
Neurosurgery. 2001 Aug;49(2):380-9; discussion 390
11504114
Neurosurgery. 2001 Jan;48(1):151-7
11152340
Nature. 2004 Nov 4;432(7013):59-67
15378069
Cell. 2002 Sep 20;110(6):673-87
12297042
Proc Natl Acad Sci U S A. 1985 Aug;82(16):5255-9
2410917
J Med Chem. 1992 Jul 24;35(15):2806-11
1495013
Science. 2001 Oct 12;294(5541):339-45
11546839
Int J Cancer. 2002 Apr 10;98(5):690-7
11920637
Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26
15459662
J Med Chem. 1993 Feb 5;36(3):363-9
8381183
J Am Chem Soc. 2006 Nov 29;128(47):15164-72
17117868
J Biol Chem. 2004 Feb 6;279(6):4862-8
14610084
Science. 2002 Apr 5;296(5565):151-5
11884718
Nat Rev Cancer. 2010 Jan;10(1):9-22
20029421
Science. 1994 Apr 22;264(5158):569-71
7512751
J Clin Oncol. 2007 May 1;25(13):1637-8
17470853
Nat Med. 2010 Aug;16(8):853-4
20689545
Curr Pharm Des. 2006;12(22):2723-47
16918408
Nat Med. 2009 Apr;15(4):392-400
19305413
Physiol Rev. 1993 Jan;73(1):161-95
8419965
Eur J Cancer. 2003 May;39(7):917-26
12706360
J Med Chem. 1997 Jul 18;40(15):2289-92
9240343
FEBS Lett. 1991 Oct 7;291(1):50-4
1718779
Science. 1987 Oct 23;238(4826):491-7
2821619
Expert Opin Investig Drugs. 2002 Dec;11(12):1765-74
12457436
Arterioscler Thromb Vasc Biol. 2002 Jun 1;22(6):927-33
12067900
Oral Oncol. 2004 Feb;40(2):228-30
14693249
Cell Mol Life Sci. 2003 Jun;60(6):1135-57
12861381
FASEB J. 1990 Aug;4(11):2868-80
2199285
Biopolymers. 1980 Nov;19(11):1943-73
6776998
Biochem Soc Trans. 2000;28(4):311-39
10961914
Chemistry. 2008;14(5):1508-17
18080261
Biochemistry. 1991 May 28;30(21):5225-9
2036389
Nature. 2004 Nov 4;432(7013):27-8
15525967
Nat Med. 2002 Jan;8(1):14-6
11786895
Cell. 1985 Jan;40(1):191-8
3155652
J Comput Aided Mol Des. 1994 Dec;8(6):709-30
7738606
Curr Opin Cell Biol. 1997 Oct;9(5):701-6
9330874
J Clin Oncol. 2007 May 1;25(13):1651-7
17470857
Nat Rev Drug Discov. 2010 Oct;9(10):804-20
20885411
J Med Chem. 2005 Jun 30;48(13):4204-7
15974570
Nature. 1984 May 3-9;309(5963):30-3
6325925
Target Oncol. 2010 Sep;5(3):175-81
20820929
Biomaterials. 2003 Nov;24(24):4385-415
12922151
Curr Opin Cell Biol. 2001 Oct;13(5):555-62
11544023
Nat Rev Drug Discov. 2004 May;3(5):391-400
15136787
Nat Rev Mol Cell Biol. 2007 Jun;8(6):464-78
17522591
J Med Chem. 1999 Aug 12;42(16):3033-40
10447947
Science. 1995 Dec 1;270(5241):1500-2
7491498
Cell. 1986 Jul 18;46(2):271-82
3487386
Cancer Res. 2008 Sep 15;68(18):7323-31
18794119
Int J Hematol. 2000 Dec;72(4):448-54
11197210
Acc Chem Res. 2008 Oct;41(10):1331-42
18636716